Background: Preterm delivery (PTD) is the leading cause of neonatal morbidity and mortality. epidemiologic studies indicate recurrence of PTD is maternally inherited, creating a strong possibility that mitochondrial variants contribute to its etiology. This study examines the association between mitochondrial genotypes and PTD and related outcomes. Methods: This study combined, through meta-analysis, two case-control, genome-wide association studies: one from the Danish National Birth cohort study and one from the Norwegian Mother and child cohort study (MoBa) conducted by the Norwegian Institute of Public health. The outcomes of PTD (≤36 wk), very PTD (≤32 wk), and preterm prelabor rupture of membranes (PPROM) were examined. a total of 135 individual single-nucleotide polymorphism (sNP) associations were tested using the combined genome from mothers and neonates (case vs. control) in each population and then pooled via meta-analysis. results: after meta-analysis, there were four sNPs for the outcome of PTD below P ≤ 0.10 and two below P ≤ 0.05. For the additional outcomes of very PTD and PPROM, there were three and four sNPs, respectively, below P ≤ 0.10. conclusion: Given the number of tests, no single sNP reached study-wide significance (P = 0.0006). Our study does not support the hypothesis that mitochondrial genetics contributes to the maternal transmission of PTD and related outcomes.
P reterm delivery (PTD; gestational age (GA) at delivery <37 wk) and its effects are the leading causes of neonatal morbidity and mortality, responsible for ~35% of infant deaths in the United States (1) and ~28% of the 4 million neonatal deaths worldwide (2) . Neonates who survive are at increased risk for blindness, deafness, cerebral palsy, and cognitive delay (3, 4) . These disorders have onset in the neonatal period, and thus cause more disability-adjusted life years than adult-onset diseases. Of concern is that rates of PTD in the United States have been rising, peaking in 2006 at 12.8% overall (11.1% in singleton births) with only slight declines since (5) .
Contributing factors to PTD are many and varied. Environmental factors including smoking (6) and other substance abuse, low socioeconomic status (7) , maternal stress (8) , extremes in maternal age (9, 10) , and previous adverse pregnancy outcomes (11) contribute to PTD. Moreover, physiological risk factors such as uterine anomalies (12) , abnormal cholesterol (13) , low vitamin D (14, 15) , maternal infection (16) , and elevated inflammatory states (17) put delivering women at risk. The multifactorial nature of this disease makes it difficult to establish broadly applicable principles about its etiology.
Underlying the established risk factors is the role genetic predisposition plays in PTD (18) . A familial component has been established with genetic studies showing that the heritability of PTD is up to 40% (19) . In addition, associations of PTD and single-nucleotide polymorphisms (SNPs) in the nuclear genome have been reported (20) (21) (22) . An underexplored, yet highly plausible, cause of the matrilineal risk for PTD is the role of the mitochondrial genome. Epidemiologic studies in two European populations indicate that recurrence of PTD is maternally associated, suggesting that mitochondrial variants may contribute to risk (23) (24) (25) . Specific case-control studies have pointed to association within the mitochondrial genome as well (26) . These indications of a mitochondrial component to PTD call for a comprehensive, genome-wide approach to identifying associated mitochondrial SNPs implicated in PTD (27) .
This study examines the link between mitochondrial genome variation, which is maternally inherited, and PTD by examining SNPs from across the mitochondrial genome. This study combines results from two mitochondria-wide scans: one from a Danish population and one from a Norwegian population.
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The results from each study were meta-analyzed to screen for any potential candidate SNPs related to PTD.
RESULTS
Case and control numbers for each study population, Danish and Norwegian, concerning the outcomes of PTD, very PTD, and preterm prelabor rupture of membranes (PPROM) are summarized in Table 1 . Mitochondrial SNPs were tested using the outcomes defined in these tables for each population and then pooled via random-effects meta-analysis. Figure 1 is a graphical representation of the results for the Denmark and Norway populations and meta-analyzed results.
In the Danish population, 9 SNPs (4 for PTD, 3 for very PTD, and 2 for PPROM) fell below P ≤ 0.05 and in the Norwegian population 12 SNPs were below P ≤ 0.05 (4 for PTD, 5 for very PTD, and 3 for PPROM). These results can be seen in Tables 2  and 3 . None of these SNPs were below P ≤ 0.05 in both populations and none approached the study-wide significance threshold (P ≤ 0.0006).
In the meta-analyzed results, for the outcome of PTD, there were a total of four SNPs that were below P ≤ 0.10 ( Table 4 ). Of these, two SNPs were below P ≤ 0.05 at positions 6777 and 5047. None of these SNPs were below P ≤ 0.05 in either the Danish or Norwegian populations alone and none approached study-wide significance (P ≤ 0.0006).
Results were similar when using the outcome of very PTD. After meta-analysis, three SNPs had P ≤ 0.10 and all were below P ≤ 0.05. Of these three, one was below P ≤ 0.05 in the Danish population and two were below P ≤ 0.05 in the Norwegian population. None approached study-wide significance (P ≤ 0.0006).
For the outcome of PPROM, four SNPs were below P ≤ 0.10 and three were below P ≤ 0.05. None of these SNPs were below P ≤ 0.05 in either the Danish or Norwegian populations and none approached study-wide significance (P ≤ 0.0006).
No individual SNP, in the Danish cohort, Norwegian cohort, or pooled meta-analysis was even on the same order of magnitude of the study-wide significance threshold, P ≤ 0.0006. Complete results for all tested SNPs are available from the authors on request.
DISCUSSION
Our analysis of mitochondrial SNPs and their relation with PTD and related outcomes did not implicate any particular locus that was significantly associated with any of the defined outcomes. This study does not support the hypothesis of a maternal link to PTD through transmission of the mitochondrial genome.
Assessing the mitochondrial impact on PTD is a necessary step in unraveling its etiology. In addition to epidemiological evidence for a mitochondrial role in PTD, biological factors point to this possibility. Oxidative stress from natural processes, both pregnancy (28) and labor (29) , as well as outside factors like toxins (30) and infection, can contribute to adverse pregnancy outcomes and would be worsened in the setting of mitochondrial dysfunction. Similarly, given the central role of the mitochondrion in energy metabolism (31) , variations in necessary processes, from mother or fetus, could lead to detrimental effects.
Mitochondrial genetics was an obvious explanation for the observed maternal link to PTD risk, but this may be explained by other modes of transmission. Genetically, the possibility of imprinting, whereby the maternal or paternal copy of a gene is expressed over the suppressed paternal or maternal copy, at key locations related to pregnancy and parturition may explain the observed inheritance pattern. Imprinting appears to be rare (32) and its impact in complex and common diseases is uncertain, but it has been shown to possibly contribute to other common conditions (33) . Alterations in the maternal nuclear genome or fetal-maternal genetic interactions could also explain the witnessed maternal inheritance. Finally, any risk factor for PTD that is preferentially passed from mother to daughter, as opposed from mother to son, could explain this association. Such possibilities include biological factors such as genital tract microflora (34) , or, conceivably, nongenetic transmission of response to social factors such as stress (35) .
This study using mitochondrial genetics did have some limitations. First, although every effort was made to include 
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Mitochondrial genetics and preterm delivery only spontaneous PTDs, it is possible that our case population included a small portion of PTDs resulting from infections. In the original Danish cohort, 12 cases (<1.5%) had documented chorioamnionitis. We believe that the additional Danish samples and the Norwegian population have similarly low infection rates, and thus our case population is appropriately homogeneous. In addition, predefined haplogroups (H, U, J, etc., for Western Europeans) were not tested because the Illumina chip did not contain the necessary SNPs to define these haplogroups in the populations. Meta-analysis of two study populations increased our power to detect any potential associated SNPs, but our study was still limited in its ability to detect the effects of rare variations. A sample size of around 5,000 cases and controls would be needed to detect an odds ratio of 2.0 for SNPs with minor allele frequency around 1%. This is especially true for the outcomes of PPROM and very PTD because of the significant decrease in the case population. Studies of the current size can only Articles Alleman et al.
detect common SNP variations with large disease risk or uncommon SNP variations with extreme impact on disease.
Traditionally, it has been thought that common SNP variations lead to common diseases, but this may not be true for all conditions (36) . Therefore, only future studies with very large sample sizes and more granular sequencing can completely assess the impact of rare variations in the mitochondrial genome on the risk of PTD. This study has several strengths that contribute to its validity. The data come from two populations that are genetically homogeneous, reducing population stratification and possible false positives. However, this may also limit the application of these results to other external populations. Definitions of PTD were clearly established for cases and controls, as they were based on last menstrual period and/or ultrasound. The case and control groups were both clean of many possible confounding conditions including any induction of delivery, multiple births, congenital malformations, preeclampsia, or other placental abnormalities.
Previous epidemiological and genetic studies indicate that genetics plays some role in the etiology of PTD. Future studies should include analyses of the effects of imprinting; a full genome-wide approach is currently under way within these same populations. Extending studies of mitochondrial genetics in a larger cohort of this population or in different ethnic populations may yield contrasting results and gene-gene and gene-environment interactions between factors such as inflammation and cholesterol are of interest. Genetic interactions in the mother and/or fetus likely play a role in the etiology of PTD. However, no obvious common mitochondrial variant was associated with any of the study outcomes in these populations.
METHODS

Study Populations
Danish Population. Mother-neonate pairs were selected as cases and controls from the Danish National Birth Cohort (DNBC) Study (37) . This cohort consisted of ~100,000 total births occurring between 1997 and 2002. Controls were defined as 39-40 wk GA and cases as infants between 20 and 36 wk GA. (Only three births were <22 wk GA. As only live-born infants were included in the study, these infants were unlikely survivors, had underestimated GA, or had a data error in their stillborn status. Underestimated GA is most likely; therefore, they have been retained in the cohort.) All four grandparents of a neonate were born in Denmark, except for 24 individuals who had one or two grandparents born in other Nordic countries. The parent genome-wide association study included 1,000 case mother-neonate pairs and 1,000 control mother-neonate pairs. Biological samples collected from mothers and neonates were stored in the Biobank at Statens Serum Institut. Of the original 2,000 mothers chosen, 1,937 were successfully genotyped. Of these, 41 mothers were removed for having GA outside the case or control definitions, 165 cases for delivery via cesarean section, 24 controls for having a previous PTD, and 2 mothers for preeclampsia. In addition, after genotyping, some mothers were identified as sisters, therefore five women were removed via random selection of one sister-neonate pair. This left 1,700 mothers for analysis (965 controls and 735 cases). Of the original 2,000 neonates chosen, 1,901 were successfully genotyped. Of these, 47 were removed for GA not within the case or control definition, 154 cases for delivery via cesarean section, 23 controls for their mothers having a previous PTD, and 2 for preeclampsia. In addition, four neonates were removed for being born to mothers who were sisters to others in the study. This left 1,671 neonates for analysis (958 controls and 713 cases).
To increase the power for SNP detection for the original genomewide association study described above, an additional set of ~500 mother-baby pairs, mostly cases, were selected from the DNBC BioBank or the Danish Newborn Screening Biobank. Of these 500 mothers, 496 were successfully genotyped and 2 were removed for GA not within the case or control range, leaving 490 cases and 4 controls. Of the 500 neonates, all were successfully genotyped and 2 were removed for GA not within the case or control range, leaving 494 cases and 4 controls. 
Common Inclusion-Exclusion Criteria
Exclusion criteria for each study were any obstetrical induction of labor (iatrogenic delivery), placental abnormalities (previa or abruption), preeclampsia, congenital malformations, stillbirths, and multiple births. All cesarean sections were removed from the case populations as well. Subjects were enrolled with the appropriate consent for future research. In both the Danish and Norwegian cohorts, the number of eligible births for this study represented ~25% of the total PTD population. Informed consent was obtained from all individuals according to each country's protocols (37, 38) and approval for this study was granted by the University of Iowa Institutional Review Board, study no. 200608748.
Genotyping
Genotyping was performed using the Illumina 
Union of Maternal and Neonatal Genetic Information
For mitochondrial data, mothers and neonates are assumed to have identical genotypes. The genetic concordance rate between maternal and neonatal pairs was 100% for all SNPs in the Danish population and >99.4% in the Norway population. Therefore, maternal and neonatal genetic information was analyzed as one individual, using the mother's genotype as the default and supplementing with the neonate's genotype if that of the mother was missing. This increased the power of the individual studies by increasing genotyping rates and increasing the number of cases and controls. Table 1 indicates the number of case and control genotypes available to be analyzed for each of the populations.
Genetic Analysis
Single SNP allelic associations were tested using χ 2 tests in both the Danish and Norwegian populations. The outcomes examined were PTD (≤36 wk GA), very PTD (≤32 wk GA), and PPROM. PPROM was defined by using the International Classification of Diseases (ICD) code in the Medical Birth Register for each country. After testing within each population, the results were meta-analyzed using a random-effects model. No correction for the number of tests was made to the reported pooled P values or odds ratios. All analyses were performed in PLINK (40) .
Of the 135 mitochondrial SNPs on the panel, a total of 88 SNPs were meta-analyzed between the two populations. The 47 SNPs removed were either not called in one of the populations or had a minor allele frequency of zero in either the cases or controls for one of the populations. For the additional 500 Danish cases and controls, only 109 SNPs were called. Given the number of SNPs tested, a conservative threshold for significance in this study would be P = 0.0006 (P = 0.05/88 SNPs).
